Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.56 |
| ▸ | CTSS | P25774 | 4/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 2/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7696221 | 0.88 | CTSK (0.59) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL3842588 | 0.88 | CTSK (0.59) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL14338698 | 0.88 | CTSK (0.59) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL21715587 | 0.86 | PPARA (0.47) | CTSKCTSSATMPPARAPPARG | |
| SCHEMBL13198524 | 0.86 | ATM (0.55) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL15159962 | 0.85 | CTSK (0.59) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL825574 | 0.84 | CTSK (0.58) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL3493706 | 0.84 | CTSK (0.58) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL4727222 | 0.84 | CTSK (0.58) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL5760296 | 0.84 | CTSK (0.58) | CTSKCTSSATMSYKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10836761-B2 | Cinchonine-derived catalysts and methods of using same | BRANDEIS UNIVERSITY (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200048243-A1 | CINCHONINE-DERIVED CATALYSTS AND METHODS OF USING SAME | BRANDEIS UNIVERSITY (US) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836761-B2 | Cinchonine-derived catalysts and methods of using same | MCM2, MCM7, MCM5 | CTSK 1231/4885CTSS 775/4885ATM 2423/4885 |
| US-20200048243-A1 | CINCHONINE-DERIVED CATALYSTS AND METHODS OF USING SAME | MCM2, MCM7, MCM5 | CTSK 1231/4885CTSS 775/4885ATM 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.